alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › aria-e

aria-e

3 studies tagged aria-e, dated 2025-08-21 to 2026-10-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Residualized occipital amyloid burden and plasma biomarker profiles in relation to ARIA-E during anti-amyloid treatment 2026-10-09
  2. Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study 2026-08-18
  3. Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment 2025-08-21

Studies

3 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Internal medicine (Tokyo, Japan) 1
  • Therapeutic advances in drug safety 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Residualized occipital amyloid burden and plasma biomarker profiles in relation to ARIA-E during anti-amyloid treatment

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-10-09 Treatments

    Disproportionate occipital amyloid burden may identify a biologically vulnerable subgroup requiring validation in larger cohorts.

  2. Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Therapeutic advances in drug safety 2026-08-18 Treatments

    FAERS included 2961 lecanemab and 1542 donanemab primary suspect reports; WHO-VigiAccess included 2525 lecanemab- and 1450 donanemab-related reports.

  3. Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Internal medicine (Tokyo, Japan) 2025-08-21 Treatments

    We herein report a case of amyloid-related imaging abnormalities (ARIA)-E/H following lecanemab treatment in a 70-year-old man with mild cognitive impairment due to Alzheimer's disease.

All topic tags with their study counts